TX-MARY-KAY
17.5.2023 18:06:31 CEST | Business Wire | Press release
Mary Kay Inc., a global leader in skin care innovation, in partnership with the European Society for Dermatological Research, recently announced its inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees at a special virtual event prior to the First International Societies for Investigative Dermatology conference in May. Grant recipients are researchers conducting groundbreaking, innovative studies in skin health and skin disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005040/en/
Mary Kay partnered with European Society for Dermatological Research (ESDR) to award inaugural Mary Kay-ESDR Skin Health/Skin Disease Research Grants. Congratulations to our 2022 recipients, Dr. Clarisse Ganier and Dr. Michael Cangkrama, who will each receive $20,000 grants to further their contributions in skin disease research. (Photo: Mary Kay Inc.)
“Mary Kay is dedicated to advancing skin and nutritional health research globally, and we know this cannot be done alone. Collaboration across industries, academic institutions, and clinicians is critical, which is why we are proud to partner with ESDR to furnish the first-ever Mary Kay-ESDR Skin Health/Skin Disease Research Grants,” said Dr. Lucy Gildea, Chief Innovation Officer, Product and Science at Mary Kay. “These grants bring this larger community together for new inspiration for the future, and Mary Kay is proud to be a part of this opportunity. We are excited to see how these recipients bring greater advancements to different aspects of skin health research.”
The Mary Kay Skin Health/Skin Disease Research Grants were announced at last year’s meeting in partnership with ESDR. The $20,000 grants were to be awarded to two researchers conducting incredible work in skin research to uncover new perspectives and invention strategies. In the months following the 2022 ESDR meeting, the company received applications from scientists across all of Europe.
The two grant awardees ultimately selected were:
- Dr. Michael Cangkrama, (Switzerland) Senior Scientist, Department of Biology, Institute of Molecular Health Sciences, ETH Zürich – Dr. Cangkrama is working on molecular and cellular mechanisms underlying the development and progression of epithelial skin cancers, the most common types of cancer in humans. His research projects will focus on investigating molecular mechanisms of squamous cancer development and the role of the tumor microenvironment using state-of-the-art approaches. He will utilize the grant to further develop his independent projects and continue to pursue positions as an independent group leader or Assistant Professor in Europe.
- Dr. Clarisse Ganier, (United Kingdom), Research Associate at the Center of Gene Therapy and Regenerative Medicine in King’s College London. Dr. Ganier is part of the Human Cell Atlas initiative – an international collaborative effort to map all cell types within the human body – to generate a comprehensive Skin Cell Atlas. As part of this work, they have created a multi-scale spatial atlas of healthy skin and basal cell carcinoma (BCC), incorporating single cell transcriptomics, in vivo optical coherence tomography, spatial global transcriptional profiling and in situ sequencing. Funding for this research will allow her to pursue her professional goals of starting her own laboratory focusing on skin cancer biology by combining multiomics data, both in vitro and ex vivo.
“Congratulations to each of our 2022 grant award recipients,” added Dr. Gildea. “These individuals were carefully chosen in collaboration with the European Society for Dermatological Research—and we are thrilled to support their research.”
“On behalf of the ESDR board, we would like to thank Mary Kay for its support of the ESDR and congratulate this year’s grant recipients for their tremendous contributions to their respective fields. A key objective of our Society is to promote innovative research in investigative dermatology and to support researchers' activities in translational skin research,” said Eli Sprecher, Chair, Scientific Program Committee of ESDR.
The sponsorship and grants, revealed leading up to the inaugural International Societies for Investigative Dermatology Conference in Tokyo, are just the latest efforts by Mary Kay to reinforce the company’s long-standing commitment to advancing skin health research and development. Mary Kay holds more than 1,600 patents for products, technologies and packaging designs in its global portfolio.
View the full Mary Kay-ESDR Skin Health/Skin Disease Research Grants Ceremony recording here.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in more than 35 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.
About European Society for Dermatological Research (ESDR)
The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of about 1100. By supporting investigative dermatology and skin research, the ESDR contributes to an in-depth understanding of skin homeostasis and toward improving the health of patients suffering from skin and venereal diseases. The ESDR facilitates the exchange of information relevant to investigative dermatology between clinicians and scientists worldwide. The ESDR also organizes educational events throughout the year to further knowledge in dermatological research. For more information, please visit: https://esdr.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Intersolar Europe: European Solar Industry Responds to Market Changes: Focus on Hybrid PV and New Financing Models24.2.2026 14:30:00 CET | Press release
The European solar market continues to grow. According to SolarPower Europe’s latest European Market Outlook, 2025 marked another strong year for photovoltaics (PV) within the European Union. When it comes to annual expansion rates, Germany is at the top of the list, followed by Spain, France, Italy and Poland. The importance of solar energy in meeting Europe’s power needs continues to grow. At the same time, many countries are changing their subsidies and financing models, creating new challenges for investors. While regulatory instruments, such as contracts for difference (CFDs), provide a new order, the industry is responding with market-based solutions, such as hybrid PV power plants and hybrid power purchase agreements (PPAs). Intersolar Europe offers guidance: At The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry at Messe München, trade visitors can experience innovations, discuss new business models and meet project developers, manufacturers a
LMR Unveils Tonka Bean CO₂ Absolute: Gourmand Excellence from Planet-Friendly Extraction24.2.2026 14:15:00 CET | Press release
True-to-nature gourmand richness achieved with renewable CO2 technology. IFF (NYSE: IFF) — LMR Naturals by IFF—a global leader in natural ingredients for perfumery, cosmetics and flavors—has introduced Tonka Bean CO₂ Absolute to its Conscious Collection, a line of 12 highly sustainable and traceable natural ingredients for perfumes and flavors. Tonka Bean CO₂ Absolute is a natural extract with a gourmand olfactive signature. This new addition to the perfumer’s palette is produced with renewable and recycled supercritical CO2 at IFF’s extraction site in Aubrac, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224233830/en/ Tonka Bean CO₂ Absolute extracted by LMR. “Our CO₂ extraction unit in Aubrac has enabled LMR to develop a collection of extracts that seamlessly blends sustainability with high hedonic profiles for perfumers," said Bertrand de Préville, general manager of LMR Naturals by IFF. "With the launch of To
NorthX Biologics and Demeetra Announce Strategic Collaboration to Deliver a Faster, Lower-Risk Path from Gene to GMP24.2.2026 14:00:00 CET | Press release
NorthX Biologics and Demeetra today announced a strategic collaboration combining a best-in-class high-titer GS (-/-) CHO cell line with full freedom to operate and no additional IP-related costs, together with advanced cell line development technologies and high-quality process development, MCB banking, and GMP manufacturing services. The collaboration is designed to help biotech companies reach IND-enabling and clinical milestones faster, with fewer technical setbacks and without the need to rebuild cell lines or re-qualify processes when transitioning to a manufacturing partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224427714/en/ Supporting stable, high-titer cell line development and seamless GMP advancement. The partnership combines Demeetra’s CleanCut™ CHO platforms and stable CLD services with NorthX Biologics’ proven GMP production capabilities, process scale-up expertise including fill and finish, and re
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 202624.2.2026 14:00:00 CET | Press release
-- The trial uses a response-driven dosing strategy and extended treatment across three prostate cancer populations, supported by the favorable clinical, pharmacokinetic and dosimetry results from Phase 1b -- AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the novel Phase 2 design of the ongoing TheraPb clinical trial of ADVC001 in metastatic prostate cancer. ADVC001 is an investigational Lead-212-based prostate-specific membrane antigen (PSMA)-targeted alpha therapy. The study design will be showcased in a ‘Trials in Progress’ poster this week at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) in San Francisco, CA. The TheraPb Phase 2 is an open-label, randomized expansion study incorporating dose optimization strategies in three groups of patients with metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). The study’s innovative d
Axelera AI Secures More Than $250 Million Funding on Global Commercial Growth24.2.2026 14:00:00 CET | Press release
European AI semiconductor leader earns backing from funds managed by Innovation Industries and SiteGround Capital along with EU institutions; edge-first architecture addresses AI's critical energy and cooling constraints Axelera AI, the European leader in AI acceleration hardware, announced its latest funding round led by Innovation Industries, with participation from prominent funds and accounts including BlackRock and SiteGround Capital as new investors, as well as existing investors Bitfury, CDP Venture Capital, European Innovation Council Fund, Federal Holding and Investment Company of Belgium (SFPIM), Invest-NL, Samsung Catalyst Fund, and Verve Investments. Axelera AI has attracted over $450 million in equity, grants and venture debt since incorporating in July 2021. The largest investment ever in an EU AI semiconductor company comes as Axelera ships to its 500th global customer across physical AI and edge AI in industries including defense and public safety, industrial manufactur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom